[Antiplatelet effects of micronized fenofibrate in subjects with dyslipidemia].

نویسندگان

  • Anetta Undas
  • Magdalena Celińiska-Löwenhoff
چکیده

INTRODUCTION Fibrates produce additional actions such as reduction of inflammatory state, insulin resistance and activation of blood coagulation, along with stimulation of fibrinolysis. It is not known whether fibrates can attenuate platelet activation. OBJECTIVES Evaluation of antiplatelet effects of fenofibrate in dyslipidemic subjects. PATIENTS AND METHODS In 20 patients (15 males, 5 females) aged 40 to 70 years who had plasma triglicerydes >1.7 mmol/l and low-density lipoprotein (LDL) cholesterol >3.4 mmol/l without diabetes, we determined plasma levels of platelet markers, soluble CD40 ligand (sCD40L) and selectin P, both in peripheral blood and samples collected every 1 minute from sites of microvascular injury prior to and following a one-month administration of micronized fibrate (160 mg/d). Results. Neither of platelet activation markers was altered following fenofibrate. We identified 7 subjects who had a significant decrease (14-21%) in velocity of the sCD40L and selectin P release after fenofibrate (p < 0.05). This subgroup was characterized by increased body mass, and posttreatment greater reduction in triglycerides and increase in high-density lipoprotein (HDL) cholesterol (p < 0.05). A decrease in the release of platelet markers was associated with a greater posttreatment reduction in plasma 8-isoprostane levels (p = 0.006). CONCLUSIONS In 1/3 of dyslipidemic subjects without diabetes, there is a decrease in platelet activation at the site of microvascular injury following a one-month administration of micronized fenofibrate. This effect can be found in individuals in whom the fibrate induced the greatest reduction in triglycerides and increase in HDL cholesterol. Moreover, antiplatelet effect of fenofibrate was associated with reduced oxidative stress.

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Metabolic and monocyte-suppressing actions of fenofibrate in patients with mixed dyslipidemia and early glucose metabolism disturbances.

The aim of this study was to compare the action of fenofibrate on monocyte cytokine release between patients with isolated mixed dyslipidemia and dyslipidemia coexisting with prediabetic states in relationship with its metabolic actions.We compared 96 primary mixed dyslipidemic patients and 29 age-, sex- and weight-matched control subjects with normal lipid profile. Depending on glucose metabol...

متن کامل

Hemostatic effects of fenofibrate in patients with mixed dyslipidemia and impaired fasting glucose.

Our study aimed to compare the effect of fenofibrate on hemostasis between patients with isolated impaired fasting glucose (IFG) and isolated mixed dyslipidemia and to examine the action of this agent on glucose and lipid metabolism. Twenty-two IFG and 23 mixed dyslipidemic patients were treated for 90 days with micronized fenofibrate (267 mg/day) and were compared with 22 age-, sex- and weight...

متن کامل

Pleiotropic Action of Short-Term Metformin and Fenofibrate Treatment, Combined With Lifestyle Intervention, in Type 2 Diabetic Patients With Mixed Dyslipidemia

OBJECTIVE To compare the effect of short-term metformin and fenofibrate treatment, administered alone or in sequence, on glucose and lipid metabolism, cardiovascular risk factors, and monocyte cytokine release in type 2 diabetic patients with mixed dyslipidemia. RESEARCH DESIGN AND METHODS We studied 128 type 2 diabetic patients with mixed dyslipidemia complying throughout the study with lifest...

متن کامل

Extralipid effects of micronized fenofibrate in dyslipidemic patients.

The aim of this study was to evaluate the levels of lipid and extralipid parameters in patients with atherogenic dyslipidemia. We investigated the lipid-lowering therapeutic efficacy of fenofibrate and its extralipid influence on oxidized low-density lipoprotein (oxLDL), C-reactive protein (CRP), Fibrinogen, factor VII and plasminogen activator type 1 (PAI-1) during 1-month treatment. Fourteen ...

متن کامل

Inhibitory effects of micronized fenofibrate on carotid atherosclerosis in patients with essential hypertension.

BACKGROUND The coexistence of hypertension and dyslipidemia synergistically increases the risk of cardiovascular events. We investigated the effect of the lipid-lowering agent micronized fenofibrate on inhibition of carotid atherosclerosis in patients with essential hypertension and mild hyperlipidemia. METHODS We measured serum lipid profiles and inflammatory markers on chemistry or immune a...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

عنوان ژورنال:
  • Polskie Archiwum Medycyny Wewnetrznej

دوره 117 5-6  شماره 

صفحات  -

تاریخ انتشار 2007